PolyNovo trade agreed

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Xceed Capital [ASX: XCD] has agreed to sell its 64 per cent stake in PolyNovo Biomaterials to Metabolic Pharmaceuticals [ASX: MBP].

The sale has been on the cards for some time, but both parties have finally signed off on the deal.

Under the arrangement Xceed, an investment company, will trade Metabolic its stake in return for 1.5 MBP shares for every PolyNovo share Xceed owns.

The deal must still be approved by both Xceed and Metabolic shareholders. Xceed is holding a shareholder's meeting to discuss the sale in November.

Related News

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd